Humasis Co. Ltd. (KOSDAQ:205470)

South Korea · Delayed Price · Currency is KRW

2,370.00

+65.00 (2.82%)

Jul 1, 2026, 3:30 PM KST

-66.45% (1Y)

Market Cap	53.63B -64.1%
Revenue (ttm)	32.87B +10.6%
Net Income	-10.43B
EPS	-469.65
Shares Out	22.63M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	26,930
Open	2,385.00
Previous Close	2,305.00
Day's Range	2,250.00 - 2,390.00
52-Week Range	2,010.00 - 7,580.00
Beta	-0.16
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 14, 2026

About Humasis

Humasis Co. Ltd. manufactures and sells pharmaceuticals and medical devices in South Korea and internationally. It offers immunodiagnostic kits, such as quantitative and qualitative tests, cardiac and cancer markers, infectious diseases, hormones, and women’s health. The company also provides bio-material products, such as COVID-19 nucleocapsid protein, human immunodeficiency virus surface proteins, COVID-19 RT-PCR kit, and COVID-19 Variant RT-qPCR kit, as well as MPXV real time PCR kit, a real-time polymerase chain reaction assay for the quali... [Read more]

Industry Medical - Specialties

Sector Healthcare

Founded 2000

Employees 60

Stock Exchange KOSDAQ

Ticker Symbol 205470

Full Company Profile

Financial Performance

In 2025, Humasis's revenue was 30.11 billion, an increase of 18.49% compared to the previous year's 25.41 billion. Losses were -15.62 billion, -48.69% less than in 2024.

Financial Statements